Proteome Sciences plc (LON:PRM)‘s stock had its “corporate” rating restated by equities researchers at FinnCap in a research note issued on Tuesday. They currently have a GBX 12 ($0.15) price objective on the stock. FinnCap’s price target suggests a potential upside of 100.00% from the company’s current price.

Shares of Proteome Sciences plc (LON:PRM) opened at 5.57575 on Tuesday. The stock’s 50 day moving average price is GBX 7.59 and its 200 day moving average price is GBX 13.35. Proteome Sciences plc has a one year low of GBX 5.00 and a one year high of GBX 23.94. The stock’s market capitalization is GBX 12.71 million.

ILLEGAL ACTIVITY WARNING: “Proteome Sciences plc’s (PRM) “Corporate” Rating Reaffirmed at FinnCap” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at

In related news, insider Roger Steven McDowell bought 2,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was acquired at an average price of GBX 5 ($0.06) per share, for a total transaction of £100,000 ($124,054.09).

About Proteome Sciences plc

Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.

Receive News & Stock Ratings for Proteome Sciences plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences plc and related stocks with our FREE daily email newsletter.